Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders
Clemens Muehlan, Cédric Vaillant, Isabelle Zenklusen, et al.
Expert Opinion on Drug Metabolism & Toxicology (2020) Vol. 16, Iss. 11, pp. 1063-1078
Closed Access | Times Cited: 70

Showing 1-25 of 70 citing articles:

Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis
Franco De Crescenzo, Gian Loreto D’Alò, Edoardo G. Ostinelli, et al.
The Lancet (2022) Vol. 400, Iss. 10347, pp. 170-184
Open Access | Times Cited: 241
The orexin story and orexin receptor antagonists for the treatment of insomnia
Clemens Muehlan, Catherine Roch, Cédric Vaillant, et al.
Journal of Sleep Research (2023) Vol. 32, Iss. 6
Open Access | Times Cited: 39
Sleep dysregulation in binge eating disorder and “food addiction”: the orexin (hypocretin) system as a potential neurobiological link
Jacqueline B. Mehr, Deborah Mitchison, Hannah E. Bowrey, et al.
Neuropsychopharmacology (2021) Vol. 46, Iss. 12, pp. 2051-2061
Open Access | Times Cited: 46
Sleep-wake and arousal dysfunctions in post-traumatic stress disorder: Role of orexin systems
Gary B. Kaplan, Gabrielle A. Lakis, Hryhoriy Zhoba
Brain Research Bulletin (2022) Vol. 186, pp. 106-122
Closed Access | Times Cited: 32
Targeting the orexin/hypocretin system for the treatment of neuropsychiatric and neurodegenerative diseases: From animal to clinical studies
Marc Ten-Blanco, África Flores, Luigia Cristino, et al.
Frontiers in Neuroendocrinology (2023) Vol. 69, pp. 101066-101066
Open Access | Times Cited: 19
Efficacy and Safety of Transitioning to Lemborexant from Z-drug, Suvorexant, and Ramelteon in Japanese Insomnia Patients: An Open-label, Multicenter Study
Motohiro Ozone, Susumu Hirota, Yu Ariyoshi, et al.
Advances in Therapy (2024) Vol. 41, Iss. 4, pp. 1728-1745
Open Access | Times Cited: 7
Emerging and upcoming therapies in insomnia
W.-H. Kim, Ho-Sook Kim
Translational and Clinical Pharmacology (2024) Vol. 32, Iss. 1, pp. 1-1
Open Access | Times Cited: 6
Seltorexant for major depressive disorder
K.L. Valentino, Kayla M. Teopiz, Sabrina Wong, et al.
Expert Opinion on Emerging Drugs (2025)
Closed Access
Discovery of IDOR-1117-1680, a dual orexin receptor antagonist with fast onset and short duration of action for the treatment of insomnia
Jean‐Philippe Surivet, Elise M. Jacob, Melanie Keßler, et al.
Bioorganic & Medicinal Chemistry (2025) Vol. 122, pp. 118132-118132
Closed Access
Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea
Marie‐Laure Boof, Jasper Dingemanse, Katharina Lederer, et al.
SLEEP (2020) Vol. 44, Iss. 6
Open Access | Times Cited: 33
Sleep–Wake Disorders in Alzheimer’s Disease: A Review
Yu-Ying Sun, Zhun Wang, He-Yan Zhou, et al.
ACS Chemical Neuroscience (2022) Vol. 13, Iss. 10, pp. 1467-1478
Closed Access | Times Cited: 19
Current Update on Clinically Relevant Sleep Issues in Parkinson’s Disease: A Narrative Review
Keisuke Suzuki
Journal of Parkinson s Disease (2021) Vol. 11, Iss. 3, pp. 971-992
Open Access | Times Cited: 26
Daridorexant for the Treatment of Insomnia
Christopher L. Robinson, Rajesh Supra, Evan Downs, et al.
Health psychology research (2022) Vol. 10, Iss. 3
Open Access | Times Cited: 15
Assessment of the effect of the dual orexin receptor antagonist daridorexant on various indices of disease severity in patients with mild to moderate obstructive sleep apnea
Marie‐Laure Boof, Mike Ufer, Ingo Fietze, et al.
Sleep Medicine (2022) Vol. 92, pp. 4-11
Open Access | Times Cited: 13
Deciphering Post-Stroke Sleep Disorders: Unveiling Neurological Mechanisms in the Realm of Brain Science
Pinqiu Chen, Wenyan Wang, Weikang Ban, et al.
Brain Sciences (2024) Vol. 14, Iss. 4, pp. 307-307
Open Access | Times Cited: 2
Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist
Benjamin Berger, Jasper Dingemanse, Giancarlo Sabattini, et al.
Clinical Pharmacokinetics (2021) Vol. 60, Iss. 10, pp. 1349-1360
Closed Access | Times Cited: 17
Insomnia
Becky Lou, Margarita Oks
Clinics in Geriatric Medicine (2021) Vol. 37, Iss. 3, pp. 401-415
Closed Access | Times Cited: 17
Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis
Uta Schilling, Andrea Henrich, Clemens Muehlan, et al.
Clinical Drug Investigation (2021) Vol. 41, Iss. 8, pp. 711-721
Closed Access | Times Cited: 17
Effect of gastric pH and of a moderate CYP3A4 inducer on the pharmacokinetics of daridorexant, a dual orexin receptor antagonist
Martine Géhin, Jolanta Wierdak, Giancarlo Sabattini, et al.
British Journal of Clinical Pharmacology (2021) Vol. 88, Iss. 2, pp. 810-819
Open Access | Times Cited: 16
Functional roles of orexin in obstructive sleep apnea: From clinical observation to mechanistic insights
Suchanya Sithirungson, Nuntigar Sonsuwan, Siriporn C. Chattipakorn, et al.
Sleep Medicine (2022) Vol. 101, pp. 40-49
Closed Access | Times Cited: 12
The Park Sleep subtype in Parkinson’s disease: from concept to clinic
Phoebe Tall, Mubasher A. Qamar, Ivana Rosenzweig, et al.
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 15, pp. 1725-1736
Open Access | Times Cited: 6
Sleep Pathologies and Eating Disorders: A Crossroad for Neurology, Psychiatry and Nutrition
Carlotta Mutti, Giulia Malagutti, Valentina Maraglino, et al.
Nutrients (2023) Vol. 15, Iss. 20, pp. 4488-4488
Open Access | Times Cited: 6
Orexins/Hypocretins and Cancer: A Neuropeptide as Emerging Target
Alain Couvineau, Nicole Pascal, Gratio Valérie, et al.
Molecules (2021) Vol. 26, Iss. 16, pp. 4849-4849
Open Access | Times Cited: 15
Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment
Benjamin Berger, Clemens Muehlan, Gernot Klein, et al.
Clinical and Translational Science (2021) Vol. 14, Iss. 6, pp. 2132-2138
Open Access | Times Cited: 13
Estradiol-dependent hypocretinergic/orexinergic behaviors throughout the estrous cycle
Hye Ji J. Kim, Samuel A. Dickie, Robert B. Laprairie
Psychopharmacology (2022) Vol. 240, Iss. 1, pp. 15-25
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top